The combination of TACE and Atez/Bev has the following theoretical advantages [15, 18, 19]: (1) TACE can effectively reduce the intrahepatic tumor burden and promote tumor-specific CD8+ T cell response by killing HCC cells and stimulate the exposure of tumor-associated antigens; (2) Bevacizumab can reshape tumor vessels, improve the immune microenvironment caused by hypoxia after TACE, and enhance the efficacy of Atezolizumab. Here, CD8A is linked to hepatocellular carcinoma.